Last reviewed · How we verify

Sichuan Jishengtang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Sichuan Jishengtang Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Shugan Jieyu Capsules Shugan Jieyu Capsules phase 3 Traditional Chinese medicine Psychiatry
Wujia Yizhi granules Wujia Yizhi granules phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. China Academy of Chinese Medical Sciences · 1 shared drug class
  2. Dongzhimen Hospital, Beijing · 1 shared drug class
  3. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
  4. Jiangsu Famous Medical Technology Co., Ltd. · 1 shared drug class
  5. Shanghai University of Traditional Chinese Medicine · 1 shared drug class
  6. Tasly Pharmaceutical Group Co., Ltd · 1 shared drug class
  7. The First Affiliated Hospital of Guangzhou Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sichuan Jishengtang Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sichuan Jishengtang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sichuan-jishengtang-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related